RELAPSED/REFRACTORY B-CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy aims to tackle tough lymphoma in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CY-219 CAR-T cells for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment involves modifying the patient's own immune cells to better recognize and attack cancer cells. The main go…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New CAR-T therapy aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis early-stage study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or stopped responding to standard therapy. RN1701 uses specially engineered immune cells from a donor to target and kill cancer cells. The main goals are to check if the …
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Experimental 'Off-the-Shelf' cell therapy targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or stopped responding to standard therapy. RN1701 uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check if the …
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Affiliated Hospital of Nantong University • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
New dual CAR-T therapy aims to tackle tough lymphoma
Disease control Not yet recruitingThis early-phase study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on lymphoma cells. It is designed for people with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the be…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Affiliated Hospital to Academy of Military Medical Sciences • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New CAR-T therapy targets hard-to-treat lymphomas in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has returned or not improved after standard therapy. RN1701 uses specially engineered immune cells (CAR-T cells) from a donor to find and attack cancer cells. The main goal is to check…
Matched conditions: RELAPSED/REFRACTORY B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 18, 2026 12:10 UTC